SGLT2 inhibitors in cardiovascular medicine

被引：23
|
作者：
Varzideh, Fahimeh [1 ,2 ]
Kansakar, Urna [1 ,2 ]
Santulli, Gaetano [1 ,2 ]
机构：
[1] Albert Einstein Coll Med, Fleischer Inst Diabet & Metab FIDAM, Einstein Mt Sinai Diabet Res Ctr ES DRC, Dept Med, 1300 Morris Pk Ave, New York, NY 10461 USA
[2] Albert Einstein Coll Med, Einstein Inst Aging Res, Wilf Family Cardiovasc Res Inst, Dept Mol Pharmacol, 1300 Morris Pk Ave, New York, NY 10461 USA
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2021年 / 7卷 / 04期
关键词：
D O I：
10.1093/ehjcvp/pvab039
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [21] Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
    Rabizadeh, Soghra
    Nakhjavani, Manouchehr
    Esteghamati, Alireza
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 17 (02)
  • [22] The effect of SGLT2 inhibitors on cardiovascular events and renal function
    Imprialos, Konstantinos P.
    Stavropoulos, Konstantinos
    Doumas, Michael
    Karagiannis, Asterios
    Athyros, Vasilios G.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1251 - 1261
  • [23] Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
    Abdullah Kaplan
    Emna Abidi
    Ahmed El-Yazbi
    Ali Eid
    George W. Booz
    Fouad A. Zouein
    Heart Failure Reviews, 2018, 23 : 419 - 437
  • [24] Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
    Pan, Runfang
    He, Yuqing
    Melisandre, Wan
    Zhang, Yunyi
    Su, Wenyuan
    Feng, Jiaming
    Jia, Chengyao
    Li, Shaoling
    Liu, Baonian
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Gragnano, Felice
    Terracciano, Fabrizia
    Calabro, Paolo
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2024, 17 (01) : 227 - 229
  • [26] Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
    Kaplan, Abdullah
    Abidi, Emna
    El-Yazbi, Ahmed
    Eid, Ali
    Booz, George W.
    Zouein, Fouad A.
    HEART FAILURE REVIEWS, 2018, 23 (03) : 419 - 437
  • [27] Can CMR Elucidate the Cardiovascular Benefit of SGLT2 Inhibitors?
    Nicholls, Stephen J.
    Nerlekar, Nitesh
    JACC-CARDIOVASCULAR IMAGING, 2021, 14 (06) : 1174 - 1176
  • [28] SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
    Wilding, John
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 379 - 381
  • [29] The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
    Ji, Peng-juan
    Zhang, Zhuo-ya
    Yan, Qi
    Cao, Hui-li
    Zhao, Ya-jing
    Yang, Bing
    Li, Jin
    ESC HEART FAILURE, 2023, 10 (02): : 1314 - 1325
  • [30] Ketoacidosis with SGLT2 Inhibitors
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1471): : 94 - 94
12345